SLC12A5 and nervous system disorder: As a result, despite a wide range of supportive preclinical evidence for KCC2 hypofunction in neurological disorders that has been reviewed in depth by others (Kaila et al., 2014; Duy et al., 2020; Tang, 2020; Belperio et al., 2022; Hegarty and Stanicka, 2022; Liedtke, 2022; Lam et al., 2023; Mcmoneagle et al., 2023; Pressey et al., 2023; Tomita et al., 2023; Mcardle et al., 2024) and outlined above, indication selection and prioritization can be more difficult to justify in these cases.